You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

TIMOPTIC-XE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Timoptic-xe patents expire, and what generic alternatives are available?

Timoptic-xe is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in TIMOPTIC-XE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Timoptic-xe

A generic version of TIMOPTIC-XE was approved as timolol maleate by MYLAN on June 8th, 1990.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TIMOPTIC-XE?
  • What are the global sales for TIMOPTIC-XE?
  • What is Average Wholesale Price for TIMOPTIC-XE?
Summary for TIMOPTIC-XE
Drug patent expirations by year for TIMOPTIC-XE
Drug Prices for TIMOPTIC-XE

See drug prices for TIMOPTIC-XE

Recent Clinical Trials for TIMOPTIC-XE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San DiegoN/A
Bausch & Lomb IncorporatedN/A
VA Northern California Health Care SystemPhase 3

See all TIMOPTIC-XE clinical trials

Pharmacology for TIMOPTIC-XE

US Patents and Regulatory Information for TIMOPTIC-XE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TIMOPTIC-XE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-001 Nov 4, 1993 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TIMOPTIC-XE

See the table below for patents covering TIMOPTIC-XE around the world.

Country Patent Number Title Estimated Expiration
Israel 50477 OPHTHALMIC COMPOSITIONS CONTAINING 1-T-BUTYLAMINO-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YLOXY)-2-PROPANOL HYDROGEN MALEATE ⤷  Sign Up
Israel 80156 PHARMACEUTICAL COMPOSITION OF THE TYPE WHICH UNDERGOES LIQUID-GEL PHASE TRANSITION ⤷  Sign Up
Ireland 862481 ⤷  Sign Up
Luxembourg 88694 ⤷  Sign Up
United Kingdom 1524405 ⤷  Sign Up
Ireland 44167 OPHTHALMIC COMPOSITIONS ⤷  Sign Up
South Africa 8607464 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TIMOPTIC-XE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0509752 C990041 Netherlands ⤷  Sign Up PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752 SPC/GB99/043 United Kingdom ⤷  Sign Up PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752 2000C/001 Belgium ⤷  Sign Up PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0227494 95C0013 Belgium ⤷  Sign Up PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752 49/1999 Austria ⤷  Sign Up PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.